- Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2a, Open-label, Dose Escalation Trial of GEN3017 with Expansion Cohorts in Relapsed or Refractory CD30+ Classical Hodgkin Lymphoma and CD30+ Non-Hodgkin Lymphoma
This study is testing a new medicine called GEN3017 for people with Hodgkin or non-Hodgkin lymphoma. It's an early-stage trial looking at safe doses and checking for side effects, as well as seeing how well the treatment shrinks the cancer.
For: Hodgkin lymphoma or non-Hodgkin lymphomaGermany · Denmark · Italy - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer
This study is testing a new medicine, TAK-280, for people with advanced cancer that can't be removed by surgery. It's an early-stage study looking at how safe the drug is, what side effects it might cause, and how the body handles it. We also want to see if it helps shrink tumours.
For: Unresectable Locally Advanced or Metastatic CancerSpain · France